Elsevier

Microvascular Research

Volume 96, November 2014, Pages 64-67
Microvascular Research

Laboratory models for the investigation of lymphangiomatosis

https://doi.org/10.1016/j.mvr.2014.08.007Get rights and content

Highlights

  • Lymphangiomatosis is an uncommon proliferative disorder of the lymphatic vasculature.

  • The etiology remains poorly understood.

  • The disease pathology is heterogeneous.

  • Several useful model systems are described.

  • Future deductive investigation of therapeutics will require more robust suitable animal models.

Abstract

Lymphangiomatosis is an uncommon proliferative disorder of the lymphatic vasculature whose etiology remains poorly understood. The lymphangiomatosis spectrum encompasses a remarkable heterogeneity in its potential presentation, including micro- and macrocystic isolated lymphatic malformations, thoracic and intraabdominal diffuse lymphangiomatosis, and osseous and soft-tissue presentations known as Gorham–Stout disease. Recent therapeutic advances are empirical in nature or, at best, inferential, reflecting the scanty availability of laboratory-based model systems for the mechanistic study of this disease. Several promising model systems are reviewed here. The laboratory investigation of lymphangiomatosis will likely continue to benefit from the remarkable growth of insights into the mechanisms of lymphangiogenesis and vascular development.

Introduction

Lymphangiomatosis is an uncommon proliferative disorder of the lymphatic vasculature, whose etiology remains poorly understood. This disease spectrum affects a patient population that is small in number, but the consequences of this pathology are potentially devastating (Rockson, 2011b). The disease can be considered a failure of normal lymphatic development (Gordon and Mortimer, 2011, Lee et al., 2005). Sites of involvement can include soft tissue, viscera, and bone (Gordon and Mortimer, 2011, Venkatramani et al., 2011). Visceral involvement carries a particularly poor prognosis. Furthermore, lymphangiomatosis can be limited to a defined organ-delimited structure (e.g., spleen, liver, and thoracic cavity) or can reflect a more generalized process (Blei, 2011).

Section snippets

The spectrum of human clinical lymphangiomatosis

The lymphangiomatosis spectrum encompasses a remarkable heterogeneity in its potential presentation. These various features should be considered in attempts to recapitulate the human pathology in suitable animal models of disease.

Isolated lymphatic malformations, also known as lymphangiomas, are low-flow vascular malformations (Perkins et al., 2010). Seventy-five percent of these lesions occur in the head and neck region. The clinical presentation is related to the size of the malformation and

Clinical therapeutic observations

Conventional non-surgical options for patients with lymphangiomatosis have been limited. In isolated cases or limited case series, some disease stabilization has been accomplished through treatment with pegylated (PEG) interferons, glucocorticoids, tyrosine kinase inhibitors, and, in the case of bony involvement, biphosponates (Ozeki et al., 2007). Of late, there has been growing enthusiasm for newer molecular interventions that have the potential for improving the outcome of these often

Three-dimensional lymphatic ring assay

This is a model that attempts to recapitulate in vivo findings within an in vitro model of lymphangiogenesis. The lymphatic ring assay recapitulates the different steps of cell sprouting from a pre-existing lymphatic vessel in a collagen environment (Bruyere et al., 2008). Thoracic ducts used for lymphatic ring cultures were collected from male and female C57BL/6 mice and 3-dimensional lymphatic ring cultures are undertaken. The ring-shaped explants embedded in rat tail interstitial collagen-I

Lymphangiomatosis is part of the lymphatic continuum

Despite the continued absence of an ideal laboratory model for lymphangiomatosis, it is apparent that lymphatic maldevelopment is central to the pathogenesis of the disorder. Thus, it is plausible to imagine that laboratory investigation of lymphangiomatosis will be the beneficiary, directly or indirectly, of the remarkable insights into the mechanisms of lymphangiogenesis that continue to expand and to be translated into therapeutic approaches to lymphatic pathology (Zheng et al., 2014).

References (55)

  • S. Mancardi

    Lymphatic endothelial tumors induced by intraperitoneal injection of incomplete Freund's adjuvant

    Exp. Cell Res.

    (1999)
  • J.A. Perkins

    Clinical and radiographic findings in children with spontaneous lymphatic malformation regression

    Otolaryngol. Head Neck Surg.

    (2008)
  • J.A. Perkins

    Lymphatic malformations: current cellular and clinical investigations

    Otolaryngol. Head Neck Surg.

    (2010)
  • D.W. Swank

    Intrathoracic lymphangiomatosis mimicking lymphangioleiomyomatosis in a young woman

    Mayo Clin. Proc.

    (1989)
  • H.D. Tazelaar

    Diffuse pulmonary lymphangiomatosis

    Hum. Pathol.

    (1993)
  • A. Alajati

    Spheroid-based engineering of a human vasculature in mice

    Nat. Methods

    (2008)
  • J. Aman

    Successful treatment of diffuse pulmonary lymphangiomatosis with bevacizumab

    Ann. Intern. Med.

    (2012)
  • F. Blei

    Lymphangiomatosis: clinical overview

    Lymphat. Res. Biol.

    (2011)
  • N. Brodszki

    A novel treatment approach for paediatric Gorham–Stout syndrome with chylothorax

    Acta Paediatr.

    (2011)
  • P. Brouillard

    Genetics of lymphatic anomalies

    J. Clin. Invest.

    (2014)
  • F. Bruyere

    Modeling lymphangiogenesis in a three-dimensional culture system

    Nat. Methods

    (2008)
  • F. Bruyere

    Does plasminogen activator inhibitor-1 drive lymphangiogenesis?

    PLoS One

    (2010)
  • G.J. Canny

    Diffuse pulmonary angiomatosis

    Thorax

    (1991)
  • E.Y. Chen

    Similar histologic features and immunohistochemical staining in microcystic and macrocystic lymphatic malformations

    Lymphat. Res. Biol.

    (2009)
  • P. Cirone

    A role for planar cell polarity signaling in angiogenesis

    Angiogenesis

    (2008)
  • T.S. Cutler

    Abdominal cystic lymphangiomatosis

    Am. Surg.

    (2010)
  • B. Detry

    Digging deeper into lymphatic vessel formation in vitro and in vivo

    BMC Cell Biol.

    (2011)
  • Cited by (0)

    1

    Allan and Tina Neill Professor of Lymphatic Research and Medicine.

    View full text